<DOC>
	<DOCNO>NCT01222936</DOCNO>
	<brief_summary>SCLC aggressive lethal form lung cancer , typically sensitive cytotoxic therapy first diagnose , associate high incidence tumour relapse poor life expectancy . Combination chemotherapy base cisplatin carboplatin etoposide represent widely use regimen . Despite high response rate , approximately 80 % patient limited disease nearly patient extend disease develop disease relapse progression . Topotecan , present , approved second line treatment Europe . The search new therapeutic agent could alter natural history SCLC would important goal reach . LBH589 ( Panobinostat ) histone deacetylase ( HDAC ) inhibitor available intravenous oral administration . LBH589 could classify PAN-DAC inhibitor target histone non histone protein could suitable combination cytotoxics . Three phase I dose escalation study intravenous oral formulation LBH589 , examine various dose schedule administration conduct advanced solid tumour haematological malignancy . Single agent activity observe phase I patient haematological cancer . In solid tumour one response ( Hormone-refractory Prostatic Cancer ) prolong stabilization observe intravenous formulation . Phase II study progress .</brief_summary>
	<brief_title>LBH Phase II Small Cell Lung Cancer ( SCLC )</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Histological/cytological diagnosis SCLC , mix small non small cell tumour exclude 2 . ≤ 2 prior chemotherapy line 3 . Progression , , last previous chemotherapy treatment 4 . Age ≥ 18 ≤ 75 year 5 . Life expectancy least 3 month 6 . ECOG Performance Status 01 7 . At least one measurable lesion accord modify RECIST criterion define ≥ 1 lesion long diameter ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan . In case solitary measurable lesion , histological confirmation require . 8 . Adequate haematological function : haemoglobin ≥ 9 g/dl platelet count ≥ 100,000/mm3 neutrophil count ≥ 1,500/mm3 9 . Adequate liver renal function : Total serum bilirubin ≤ 1.5 x UNL Serum creatinine ≤ 1.5 x UNL 24 hour creatinine clearance ≥ 50 mL/min AST ALT ≤ 2.5 x UNL ≤ 5.0 x UNL transaminase elevation due hepatic involvement Albumin ≥ 2.5 g/dl Alkaline phosphatase ≤ 2.5 x UNL 10 . Fertile patient must use effective contraception ≥ 6 week completion study therapy 11 . Ability sign informed consent 1 . Progression previous chemotherapy 2 . Other chemotherapy treatment &lt; 4 week prior enrolment 3 . Presence active infection 4 . A known history HIV positivity 5 . Participation investigational drug study &lt; 4 week precede study enrolment 6 . Radiotherapy involve &gt; 30 % active bone marrow 7 . Thoracic brain radiotherapy &lt; 4 week prior enrolment . Palliative radiotherapy allow study treatment 8 . Presence serious neurological psychiatric disorder 9 . Impaired cardiac function , include one following : Complete Left Bundle Branch Block obligate use cardiac pacemaker congenital long QT syndrome history presence atrial ventricular tachyarrhythmias clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTcF &gt; 480 msec screen ECG Right Bundle Branch block + leave anterior hemiblock ( biphasic block ) Acute MI ≤ 3 month prior start study drug Other clinically significant heart disease ( e.g . congestive heart failure , previous history angina pectoris , uncontrolled hypertension , history labile hypertension arrhythmia , history poor compliance antihypertensive regimen ) Any case current abnormal cardiac functionality history cardiac disease cause LVEF &lt; 45 % determine ECHO 10 . Known hypersensitivity/allergic reaction study product 11 . Presence uncontrolled intercurrent illness condition judgement investigator would place subject undue risk interfere result study . 12 . Previous current concomitant malignancy site , basal squamous cell carcinoma skin carcinoma situ uterine cervix , within 3 year . 13 . Symptomatic progressive brain metastasis 14 . Patients active bleed diathesis anticoagulant Therapeutic dos sodium warfarin ( Coumadin ) allow . Low dos Coumadin ( e.g. , ≤ 2 mg/day ) line patency allow 15 . Pregnant lactate woman 16 . Concomitant use CYP3A4/5 inhibitor inducer , drug prolong QT interval and/or induce torsades ventricular arrythmia , treatment discontinue switched different medication prior start study drug . 17 . Treatment hematopoietic colonystimulating growth factor ( e.g. , GCSF , GMCSF ) ≤ 2 week prior start study drug . 18 . Unable unwilling comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>LBH581</keyword>
	<keyword>Panobinostat</keyword>
	<keyword>Small Cell Lung Carcinoma</keyword>
</DOC>